MJN110

MJN110 is a potent, selective, and irreversible small-molecule inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG). By covalently inhibiting MAGL, MJN110 significantly elevates 2-AG levels in both the central nervous system and peripheral tissues, which subsequently activates CB1 and CB2 cannabinoid receptors to produce analgesic, anti-inflammatory, and anxiolytic effects. In preclinical studies, MJN110 has demonstrated efficacy in reducing mechanical allodynia and thermal hyperalgesia in various models, including neuropathic pain and chronic pain associated with sickle cell disease, without inducing the typical cannabinoid-like side effects at therapeutic doses. It was developed as a pharmacological tool to investigate the therapeutic potential of the endocannabinoid system and is widely used in preclinical research.